JP2021512852A5 - - Google Patents

Info

Publication number
JP2021512852A5
JP2021512852A5 JP2020538791A JP2020538791A JP2021512852A5 JP 2021512852 A5 JP2021512852 A5 JP 2021512852A5 JP 2020538791 A JP2020538791 A JP 2020538791A JP 2020538791 A JP2020538791 A JP 2020538791A JP 2021512852 A5 JP2021512852 A5 JP 2021512852A5
Authority
JP
Japan
Prior art keywords
article
coating according
compound
coating
steroids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020538791A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512852A (ja
JP7502186B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2019/050135 external-priority patent/WO2019148293A1/en
Publication of JP2021512852A publication Critical patent/JP2021512852A/ja
Publication of JP2021512852A5 publication Critical patent/JP2021512852A5/ja
Application granted granted Critical
Publication of JP7502186B2 publication Critical patent/JP7502186B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020538791A 2018-02-02 2019-02-01 ステロイド二量体を含むガラス製剤およびその使用 Active JP7502186B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862625460P 2018-02-02 2018-02-02
US62/625,460 2018-02-02
US201862627608P 2018-02-07 2018-02-07
US62/627,608 2018-02-07
US201862758234P 2018-11-09 2018-11-09
US62/758,234 2018-11-09
PCT/CA2019/050135 WO2019148293A1 (en) 2018-02-02 2019-02-01 Glass formulations comprising steroid dimers and uses thereof

Publications (3)

Publication Number Publication Date
JP2021512852A JP2021512852A (ja) 2021-05-20
JP2021512852A5 true JP2021512852A5 (enExample) 2022-01-31
JP7502186B2 JP7502186B2 (ja) 2024-06-18

Family

ID=67479137

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020538791A Active JP7502186B2 (ja) 2018-02-02 2019-02-01 ステロイド二量体を含むガラス製剤およびその使用

Country Status (9)

Country Link
US (9) US20210113457A1 (enExample)
EP (1) EP3740494A4 (enExample)
JP (1) JP7502186B2 (enExample)
KR (1) KR102952719B1 (enExample)
CN (1) CN111971292B (enExample)
AU (1) AU2019214347B2 (enExample)
CA (1) CA3087898A1 (enExample)
MX (1) MX2020008017A (enExample)
WO (3) WO2019148294A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019148294A1 (en) 2018-02-02 2019-08-08 Interface Biologics, Inc. Dimeric dexamethasone prodrug compositions and uses thereof
US12473326B2 (en) 2019-02-01 2025-11-18 Ripple Therapeutics Corporation Crystalline forms of dexamethasone dimers and uses thereof
CN114599406A (zh) * 2019-07-10 2022-06-07 波纹疗法公司 包含二聚类固醇前药的表面涂层和可植入装置及其用途
JP2022541341A (ja) * 2019-07-25 2022-09-22 リップル セラピューティクス コーポレーション ステロイド二量体を含む物品と治療剤の送達におけるそれらの使用
US20220347305A1 (en) 2019-08-07 2022-11-03 Ripple Therapeutics Corporation Controlled release drug dimers
CN111485325A (zh) * 2020-04-16 2020-08-04 青岛科技大学 一种耐高温的抗菌纳米纤维无纺布及其制备方法和用途
WO2021220061A2 (en) 2020-05-01 2021-11-04 Ripple Therapeutics Corporation Heterodimer compositions and methods for the treatment of ocular disorders
EP4108231A1 (en) 2021-06-25 2022-12-28 Johann-Wolfgang-Goethe-Universität Frankfurt am Main In-situ dissolving electrospun polymer fibers for ocular drug delivery
US20250057962A1 (en) * 2021-11-03 2025-02-20 Ripple Therapeutics Corporation Processable compositions and use for the same
WO2024013565A1 (en) * 2022-07-12 2024-01-18 Ripple Therapeutics Corporation Compositions and methods for improving vision
JP2026511169A (ja) * 2023-03-23 2026-04-10 プレシディア バイオセラピューティクス インコーポレイテッド プロドラッグ、プロドラッグ組成物及び関連方法
TR2024002978A1 (tr) * 2024-03-12 2025-09-22 İstanbul Tekni̇k Üni̇versi̇tesi̇ Elektroeği̇rme yöntemi̇yle elde edi̇len ve i̇laç yüklü bi̇yopoli̇mer nanoli̇flerle kaplanan göz i̇mplanti üreti̇m yöntemi̇

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1058886A (en) 1910-04-13 1913-04-15 Alfred Mueller Firing mechanism for firearms.
FR7604M (enExample) 1968-04-22 1970-01-19
DE1768345B2 (de) * 1968-05-03 1976-12-02 Hoechst Ag, 6000 Frankfurt Dimere steroid-21-alkylcarbonate und verfahren zu ihrer herstellung
US4024871A (en) 1975-07-23 1977-05-24 Ethicon, Inc. Antimicrobial sutures
US4532316A (en) 1984-05-29 1985-07-30 W. L. Gore & Assoc., Inc. Phase separating polyurethane prepolymers and elastomers prepared by reacting a polyol having a molecular weight of 600-3500 and isocyanate and a low molecular weight chain extender in which the ratios of reactants have a limited range
PL257230A1 (en) 1985-12-31 1988-03-03 Zaklad Polimerow Pan Novel segmented polymer and method of obtaining them
IL88003A (en) 1987-10-16 1992-11-15 Dainippon Pharmaceutical Co Quinoline derivatives,their preparation and pharmaceutical compositions containing them
US4916193A (en) 1987-12-17 1990-04-10 Allied-Signal Inc. Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides
NZ240846A (en) * 1990-12-06 1994-04-27 Hoechst Ag Dimeric bile acid derivatives; preparatory processes and pharmaceutical compositions
US5321099A (en) 1992-01-02 1994-06-14 The Dow Chemical Company Blends of semi-crystalline polyamides and polyesteramides
US5217493A (en) 1992-03-11 1993-06-08 Board Of Regents, The University Of Texas System Antibacterial coated medical implants
TW289020B (enExample) * 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
IT1270836B (it) 1993-10-27 1997-05-13 Archimica Spa Procedimento per la preparazione di rufloxacina e suoi sali
EP0740650B1 (en) * 1994-01-28 2004-05-26 University Of Kentucky Research Foundation Codrugs as a method of controlled drug delivery
US6051576A (en) 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US5387598A (en) 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen
US5578621A (en) 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives
ES2161201T3 (es) 1994-04-13 2002-12-01 Romark Lab Lc Derivados de benzamida, composiciones que contienen dichos derivados ysu empleo.
US5965590A (en) 1994-09-08 1999-10-12 Romark Lab Lc Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
US5968961A (en) 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
US5859038A (en) 1994-09-08 1999-01-12 Romark Laboratories, L.C. Method for treatment of helicobacter pylori infections
MX9604483A (es) 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5856348A (en) 1994-09-08 1999-01-05 Romark Laboratories, L.C. Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide
DE19521642C2 (de) 1995-06-14 2000-11-09 Aesculap Ag & Co Kg Implantat, seine Verwendung in der Chirurgie und Verfahren zu seiner Herstellung
NZ313583A (en) 1995-08-03 1999-01-28 Paul J Santerre Fluoroligomer surface modifiers for polymers
JP4341986B2 (ja) 1996-02-15 2009-10-14 インターフェイス バイオロジックス インコーポレイテッド 生体応答性、薬理学的活性重合体及びこれから製造された物品
KR0176334B1 (ko) 1996-08-19 1999-04-01 박원훈 내인체 감염성 삽입금속표면의 코팅방법 및 그 치료기술
US5728751A (en) 1996-11-25 1998-03-17 Meadox Medicals, Inc. Bonding bio-active materials to substrate surfaces
DE69827417T2 (de) 1997-05-07 2005-10-27 Romark Laboratories, L.C., Tampa Tizoxanide und/oder Nitazoxanide enthaltende pharmazeutische Zubereitungen
TR200001021T2 (tr) 1997-07-18 2000-09-21 Infimed Inc. Aktif maddelerin kontrollü salınması için biyo aşındırılabilir makromerler.
HN1998000106A (es) 1997-08-01 1999-01-08 Pfizer Prod Inc Composiciones parenterales de alatroflaxacino
CA2302508C (en) 1997-09-10 2011-03-15 Rutgers, The State University Of New Jersey Polyanhydrides with therapeutically useful degradation products
US6468519B1 (en) 1997-09-10 2002-10-22 Rutgers, The State University Of New Jersey Polyanhydrides with biologically active degradation products
AU760408B2 (en) 1998-04-27 2003-05-15 Surmodics, Inc. Bioactive agent release coating
CA2340652C (en) 1998-08-20 2013-09-24 Cook Incorporated Coated implantable medical device comprising paclitaxel
IL147037A0 (en) 1999-07-27 2002-08-14 Phylos Inc Peptide acceptor ligation methods
CA2771263A1 (en) 2000-07-27 2002-02-07 Rutgers, The State University Therapeutic polyesters and polyamides
WO2002009769A2 (en) 2000-07-27 2002-02-07 Rutgers, The State University Of New Jersey Therapeutic azo-compounds for drug delivery
CN1520297A (zh) 2001-04-26 2004-08-11 ���ߵ���Ƶϵͳ��˾ 包含复合药物(codrugs)的缓释药物传递系统
CA2349989A1 (en) 2001-06-07 2002-12-07 Paul J. Santerre Bioactive surface modifiers for polymers and articles made therefrom
US9056048B2 (en) 2001-08-16 2015-06-16 The Trustees Of The University Of Pennsylvania Synthesis and use of cationic steroids for anti-inflammatory drug therapy
US20030158598A1 (en) 2001-09-17 2003-08-21 Control Delivery Systems, Inc. System for sustained-release delivery of anti-inflammatory agents from a coated medical device
PL369336A1 (en) 2001-09-21 2005-04-18 The Administrators Of The Tulane Educational Fund Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
AUPR879601A0 (en) 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
WO2003043657A1 (en) 2001-11-19 2003-05-30 Control Delivery Systems, Inc. Topical delivery of codrugs
US20050164994A1 (en) 2001-12-10 2005-07-28 Control Deliver Systems, Inc. Treatment of genitourinary tract disorders
MXPA04006875A (es) 2002-01-18 2004-12-06 Control Delivery Sys Inc Sistema de gel polimerico para suministro controlado de cofarmacos.
CA2493748A1 (en) 2002-08-14 2004-02-26 Medical College Of Georgia Research Institute, Inc. Methods and compositions for treatment of macular and retinal disease
TW200500067A (en) 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
EP1633403A2 (en) 2003-05-21 2006-03-15 Control Delivery Systems, Inc. Codrugs of diclofenac
CN1906207A (zh) 2004-01-15 2007-01-31 沃纳奇尔科特公司 乙炔雌二醇的二-甾族前体药物
CN1964748A (zh) 2004-04-06 2007-05-16 苏莫迪克斯公司 用于生物活性剂的涂料组合物
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
CA2571320C (en) 2004-05-14 2016-05-10 Paul J. Santerre Polymeric coupling agents and pharmaceutically-active polymers made therefrom
EP1744787A4 (en) 2004-05-14 2011-04-06 Interface Biologics Inc POLYMER COUPLING AGENTS AND PHARMACEUTICALLY ACTIVE POLYMERS MANUFACTURED THEREOF
CA2467321A1 (en) 2004-05-14 2005-11-14 Paul J. Santerre Polymeric coupling agents and pharmaceutically-active polymers made therefrom
WO2009124386A1 (en) 2008-04-07 2009-10-15 Interface Biologics Inc. Combination therapy for the treatment of bacterial infections
US8461171B2 (en) 2010-02-09 2013-06-11 QRxPharma Ltd. Hybrid opioid compounds and compositions
WO2011120044A1 (en) 2010-03-26 2011-09-29 Duke University Conjugated neuroactive steroid compositions and methods of use
US8968626B2 (en) 2011-01-31 2015-03-03 Arsenal Medical, Inc. Electrospinning process for manufacture of multi-layered structures
WO2013106528A1 (en) 2012-01-10 2013-07-18 Virginia Commonwealth University Bivalent ligands for the treatment of neurological disorders
CN105025929A (zh) 2013-03-08 2015-11-04 阿勒根公司 环孢菌素a-类固醇缀合物
JP6518198B2 (ja) 2013-03-15 2019-05-22 インターフェース バイオロジクス,インコーポレーテッド 薬物放出のための化合物及び組成物
HUE036084T2 (hu) 2014-04-28 2018-06-28 Orphomed Inc Buprenorfin dimer és alkalmazása gasztrointesztinális rendellenességek kezelésénél
EP3696185A1 (en) * 2015-11-12 2020-08-19 Board of Regents of the University of Nebraska Polyethylene glycol-conjugated glucocorticoid prodrugs and compositions and methods thereof
WO2019148294A1 (en) 2018-02-02 2019-08-08 Interface Biologics, Inc. Dimeric dexamethasone prodrug compositions and uses thereof
US12473326B2 (en) 2019-02-01 2025-11-18 Ripple Therapeutics Corporation Crystalline forms of dexamethasone dimers and uses thereof
CN114599406A (zh) 2019-07-10 2022-06-07 波纹疗法公司 包含二聚类固醇前药的表面涂层和可植入装置及其用途
JP2022541341A (ja) 2019-07-25 2022-09-22 リップル セラピューティクス コーポレーション ステロイド二量体を含む物品と治療剤の送達におけるそれらの使用

Similar Documents

Publication Publication Date Title
DE69232925T2 (de) Angiostatische steroide
CN111971292B (zh) 包含类固醇二聚体的玻璃制剂及其用途
PL207955B1 (pl) 17α-Alkilo-17ß-oksy-estratrieny, ich zastosowanie oraz preparaty farmaceutyczne je zawierające
JP2009538879A (ja) 後眼部の疾患治療用のステロイドプロドラッグの使用
JP2002520287A (ja) 黄斑変性における血管新生の予防的治療
JP2010511730A (ja) テストステロンおよびプロゲスターゲンを用いたドライアイのための処置
EP1755616A2 (en) Treatment of ophthalmic conditions with mineralcorticoids
JP2002539263A (ja) 徐放性副腎皮質ステロイドによる網膜症の治療方法または防止方法
WO2011009530A2 (de) 17-hydroxy-17-pentafluorethyl-estra-4,9 (10)-dien-11-acyloxyalkylenphenyl-derivate, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von krankheiten
JP2007535367A5 (enExample)
JP2015506983A5 (enExample)
US20070238714A1 (en) Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
JP2022548464A (ja) 二量体ステロイドプロドラッグを含む表面コーティングおよび埋込み可能なデバイス、およびその使用
CN100431544C (zh) 用于治疗病理性眼血管生成的糖皮质激素制剂
EP2941437A1 (en) Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
CA2064478C (en) Ophthalmic composition
JP2013523748A5 (enExample)
US20090029954A1 (en) Progesterone-receptor antagonist for use in brca alone or as combination with antiestrogen
US20080261929A1 (en) Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in brca mediated diseases
US20060094664A1 (en) Deoxycholic acid derivatives for the treatment of acute dysfunctions of portal and hepatic venous circulation
US20250387410A1 (en) Treatment of anti-vegf refractory ophthalmic retinal eye conditions
CA2620346A1 (en) Control of induced elevated intraocular pressure
JP2025507416A5 (enExample)
EP1781301A2 (en) Angiostatic agents for controlling choroidal neovascularisation after ocular surgery or trauma
CN101094690A (zh) 用于治疗眼后节的组合物及方法